NCT04073316View on ClinicalTrials.gov

AntiCoagulants and COGnition

PHASE4UnknownINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 13, 2020

Primary Completion Date

February 28, 2023

Study Completion Date

February 28, 2023

Conditions
Nonvalvular Atrial Fibrillation
Interventions
DRUG

Rivaroxaban 20 MG

Rivaroxaban intake, 20mg/day

DRUG

Warfarin

Warfarin intake, with target INR range between 2 and 3

Trial Locations (1)

49933 cedex 9

RECRUITING

Angers University Hospital, Angers

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

University Hospital, Angers

OTHER_GOV